semaglutide and atrial fibrillation ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome A SHOCKING CASE OF SEMAGLUTIDE-INDUCED

To maintain compound integrity, the peptide is supplied in a stable lyophilized form

Retatrutide is the first triple-agonist GLP-1/GIP/Glucagon medication in Phase 3 trials, made by Eli Lilly

Compounded alternatives bring that cost down dramatically, but the quality gap between providers varies enormously

These drugs were originally developed to treat type 2 diabetes, but they have now been linked to multiple cardiovascular benefits and significant weight loss in patients with and without diabetes

Follow-up consultations are required every six months for active treatment plans and every nine months for maintenance dosing